CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis
SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / January 9, 2025 / CAGE Bio, Inc., a clinical-stage biotechnology company advancing innovative ...
News Medical14h
New test predicts lung cancer survival better than current standards
Researchers at the Francis Crick Institute, the UCL Cancer Institute and UCLH have shown that a test called ORACLE can predict lung cancer survival at the point of diagnosis better than currently used ...
Cathay Pacific returns to Rome this summer
Announcing our 12th European destination, and another step closer to the Group’s target of reaching 100 global destinations ...